Cargando…

The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer

The management of Stage III non-small cell lung cancer (NSCLC) is complex and requires multidisciplinary input. Since the publication of the PACIFIC trial (consolidative durvalumab post concurrent chemotherapy and radiation in Stage III disease) which showed improved survival for patients in the imm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perdrizet, Kirstin, Cheema, Parneet K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700596/ https://www.ncbi.nlm.nih.gov/pubmed/34940090 http://dx.doi.org/10.3390/curroncol28060451

Ejemplares similares

A Canadian Perspective on the Challenges for Delivery of Curative-Intent Therapy in Stage III Unresectable Non-Small Cell Lung Cancer
por: Brade, Anthony, et al.
Publicado: (2021)

Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer
por: Baudoux, Nathalie, et al.
Publicado: (2023)

Immunotherapy in inoperable stage III non-small cell lung cancer: a review
por: Jain, Natasha A, et al.
Publicado: (2019)

The evolving role of radiotherapy in non-small cell lung cancer
por: Brown, Sean, et al.
Publicado: (2019)

Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy
por: Kumar, Sameera S., et al.
Publicado: (2017)

Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2021)

Second and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in Canada
por: Perdrizet, Kirstin, et al.
Publicado: (2021)

Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer
por: Melosky, Barbara L., et al.
Publicado: (2023)

Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
por: Sher, David J.
Publicado: (2017)

Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy
por: Yang, Zhang-Ru, et al.
Publicado: (2020)

Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non-small cell lung cancer
por: Lu, Xiaojuan, et al.
Publicado: (2022)

Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerations
por: Sim, Jae Kyeom, et al.
Publicado: (2023)

Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care
por: Sheffield, Brandon S., et al.
Publicado: (2022)

Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
por: Shukla, Nikhil, et al.
Publicado: (2021)

Immunotherapy for extensive stage small cell lung cancer
por: Pacheco, Jose M.
Publicado: (2020)

Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: El Sayed, Rola, et al.
Publicado: (2021)

Editorial: The Evolving Role of Immunotherapy in Non-Melanoma Skin Cancers
por: Guida, Michele, et al.
Publicado: (2022)

Radiation Dose Escalation in Stage III Non-Small-Cell Lung Cancer
por: Terakedis, Breanne, et al.
Publicado: (2011)

Therapeutic management options for stage III non-small cell lung cancer
por: Yoon, Stephanie M, et al.
Publicado: (2017)

Prognostic Factors in Stage III Non-Small-Cell Lung Cancer Patients
por: Urvay, Semiha Elmaci, et al.
Publicado: (2016)

Targeted therapies for unresectable stage III non-small cell lung cancer
por: Remon, Jordi, et al.
Publicado: (2021)

Induction treatment in patients with stage III non-small cell lung cancer
por: Palmero, Ramón, et al.
Publicado: (2021)

Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options
por: Petrella, Francesco, et al.
Publicado: (2023)

Unanticipated Radiation Replanning for Stage III Non-small Cell Lung Cancer
por: Mushonga, Melinda, et al.
Publicado: (2023)

Resectable non-small cell lung cancer: an evolving landscape
por: Loh, Jerold, et al.
Publicado: (2022)

Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?
por: Hida, Toyoaki, et al.
Publicado: (2020)

International expert consensus on immunotherapy for early-stage non-small cell lung cancer
por: Liang, Wenhua, et al.
Publicado: (2022)

Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer
por: Ionescu, Diana N., et al.
Publicado: (2022)

Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2020)

Potential role of immunotherapy in advanced non-small-cell lung cancer
por: de Mello, Ramon Andrade, et al.
Publicado: (2016)

Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer
por: Miura, Yosuke, et al.
Publicado: (2018)

Immunotherapy for Non-Small Cell Lung Cancer
por: Yoon, Sung Ho
Publicado: (2014)

The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature
por: Tsiouprou, Ioanna, et al.
Publicado: (2019)

Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer
por: Cheruvu, Praveena, et al.
Publicado: (2011)

Long-term Survival of Locally Advanced Stage III Non-small Cell Lung Cancer Patients Treated with Chemoradiotherapy and Perspectives for The Treatment with Immunotherapy
por: Vrankar, Martina, et al.
Publicado: (2018)

Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study
por: Ouwens, Mario, et al.
Publicado: (2021)

Induction Immunotherapy Followed by Thoracic Radiation without Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Case Series
por: Dasari, Srikiran, et al.
Publicado: (2022)

Concurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer
por: Kang, Ki Mun, et al.
Publicado: (2012)

Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer
por: Conibear, John
Publicado: (2020)

The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers
por: Sabari, Joshua K, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n24f2us1u8edaa92cs6csd7av8